The significant EPS miss and widening losses are concerning, but the strong cash position and FDA endorsement of a surrogate endpoint de-risk the regulatory path. Traders should watch for SAFEGUARD enrollment updates and any partnership or licensing announcements that could validate the platform beyond T1D.
SABS drugs
SABS drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 12 $3.62entry
- T+1 · 6mo ago +9.39%α +8.82% · $3.96
- T+5 · 6mo ago −1.66%α −1.74% · $3.56
- T+20 · 5mo ago −8.56%α −6.84% · $3.31
- T+60 · 3mo ago +6.35%α +1.97% · $3.85
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
SAB Biotherapeutics reported Q1 2026 EPS of -$0.35, a 68.3% miss vs consensus of -$0.21, with net loss widening to $18.9M from $5.2M a year ago. The company highlighted continued SAFEGUARD trial enrollment progress, FDA acceptance of C-peptide as a surrogate endpoint for accelerated approval, and a strong $217.6M cash position providing runway through 2028.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.35 missed consensus of -$0.21 by 68.3%
- Net loss widened to $18.9M from $5.2M in Q1 2025
- R&D expenses increased to $13.4M from $7.7M YoY
- Cash position of $217.6M at March 31, 2026, providing runway through 2028
- Completed public offering raising $95M in gross proceeds in March 2026
- SAFEGUARD Phase 2b trial enrollment on track for completion by end of 2026 with topline data expected in 2H 2027
- FDA confirmed C-peptide AUC may serve as surrogate endpoint for accelerated approval
- Phase 1 data showed C-peptide preservation and improved glycemic control in treated patients
Financial Impact
EPS miss of 68.3% vs consensus; net loss increased 263% YoY to $18.9M
Risk Factors
- Clinical trial failure or delay in SAFEGUARD could wipe out pipeline value
- Cash burn rate is accelerating; $217.6M may not be sufficient if trials extend beyond 2028
- Dilution risk from additional capital raises given ongoing losses
- Competition from other T1D disease-modifying therapies (e.g., Teplizumab)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292726 |
Track record
15 reports on SABS
2 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +15.67% at T+20 after the Oct 13, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $2.96 Now $3.00 +1.35% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $2.94 Now $3.00 +2.04% settles Dec 4
- Oct 22, 202625d ago 25-NSE Neutral 2/10 Entry $2.84 Now $3.00 +5.63% settles Nov 20
- Oct 13, 20264w ago 8-K Bullish 6/10 Entry $2.68 to $3.07 Now $3.00 +11.94% ▲ +14.55% +18.16% vs SPY
- Oct 13, 20264w ago Press Release Bullish 5/10 Entry $2.68 to $3.10 Now $3.00 +11.94% ▲ +15.67% +19.34% vs SPY
- Jul 7, 202618w ago 8-K Bullish 4/10 Entry $3.90 to $3.79 Now $3.00 −23.08% ▼ −2.82% −4.15% vs SPY
- May 29, 202624w ago Press Release Neutral 3/10 Entry $3.60 to $3.90 Now $3.00 −16.67% ▲ +8.33% +10.13% vs SPY
- May 12, 202626w ago Press Release Bearish 7/10 Viewing Entry $3.62 to $3.31 Now $3.00 +17.13% ▲ +8.56% +6.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers